CClinicalTrials.gg
Sign In
Not yet recruitingNCT07859202Updated Oct 5, 2026

The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.

A Phase 3 interventional study of W2505 and W2505-P1 in Erectile Dysfunctions, sponsored by GL Pharm Tech Corporation. Not yet recruiting at 1 site in South Korea. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by GL Pharm Tech Corporation · Phase 3, Interventional, and Treatment

Updated Oct 5, 2026Newly registeredGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of W2505.

Read the detailed description

The purpose of this study is to evaluate the efficacy and safety of W2505 in patients with erectile dysfunction.

02

Conditions studied

  • Erectile Dysfunctions

Browse trials for

03

In context

Erectile Dysfunction

683 studies on the registry are indexed under Erectile Dysfunction; 117 are open to participants now.

This study's planned enrollment of 228 is above the median of 72 across 542 interventional studies indexed under Erectile Dysfunction.

Browse Erectile Dysfunction studies →

Lead sponsor

GL Pharm Tech Corporation is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Male aged 19 years or older.
  • Capable of completing study diaries and questionnaires independently.
  • Signed written informed consent.
  • run-in medication compliance ≥ 70%

Exclusion criteria

Exclusion Criteria:

  • Primary hypoactive sexual desire.
  • Erectile dysfunction caused by premature ejaculation or untreated endocrine disorders (e.g., untreated hypogonadism, hyperprolactinemia).
  • Other exclusions applied.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    Experimental

    W2505 and W2505-P2, 12 weeks.

    Drug: W2505 · Drug: W2505-P2

  • Placebo comparator
    Placebo Comparator

    W2505-P1 and W2505-P2, 12 weeks.

    Drug: W2505-P1 · Drug: W2505-P2

  • Active comparator
    Active Comparator

    W2505-P1 and W2505-R, 12 weeks.

    Drug: W2505-P1 · Drug: W2505-R

Interventions

  • DrugW2505

    PO, Once daily(QD), 12 weeks

  • DrugW2505-P1

    PO, Once daily(QD), 12 weeks

  • DrugW2505-R

    PO, Once daily(QD), 12 weeks

  • DrugW2505-P2

    PO, Once daily(QD), 12 weeks

06

What researchers measure

Primary outcomes

  1. Change from Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score

    Change from baseline in the erectile function domain score assessed using the International Index of Erectile Function (IIEF) questionnaire.

    Time frame: Baseline, Week 12

07

Study locations

1 site
  • Inha University Hospital
    Incheon, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859202
Lead sponsor
GL Pharm Tech Corporation
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Erectile Dysfunction→

Other studies from this sponsor

GL Pharm Tech Corporation

Start the discussion